Rabies
Conditions
Keywords
Vaccine
Brief summary
This is a first-in-human, open-label, dose escalation, phase I clinical trial to assess the safety and immunogenicity of the candidate ChAdOx2 RabG vaccine in healthy UK volunteers aged 18-65. The vaccine will be administered intramuscularly (IM).
Detailed description
Volunteers will be recruited and vaccinated at the Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Oxford. There will be 3 study groups and it is anticipated that a total of 12 volunteers will be enrolled. Staggered enrolment will apply between study groups and for the first three volunteers within each group. The study includes an optional extended follow-up period, lasting one month and starting one year after vaccination. Volunteers will receive a complete pre-exposure prophylactic course of an existing rabies vaccine, allowing study of the immunological memory (recall response) induced by ChAdOx2 RabG. A second optional element of the study is the collection of saliva samples at each visit for the study of shedding of EBV and CMV.
Interventions
BIOLOGICALChAdOx2 RabG
Single dose of ChAdOx2 RabG at different concentrations: 5 x 10\^9 vp, 2.5 x 10\^10 vp, 5 x 10\^10 vp
BIOLOGICALInactivated Rabies Vaccine
A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units.
Sponsors
University of Oxford
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy adults aged 18 to 65 years. 2. Able and willing (in the Investigator's opinion) to comply with all study requirements. 3. Willing to allow the investigators to discuss the volunteer's medical history with their GP. 4. For females only, willingness to practice continuous effective contraception during the study and a negative pregnancy test on the day(s) of screening and vaccination(s). 5. Agreement to refrain from blood donation during the course of the study. 6. Provide written informed consent.
Exclusion criteria
1. Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period. To be re- confirmed at the enrolment visit. 2. Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data (e.g. Adenovirus vectored vaccine). 3. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate. 4. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed). 5. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. 6. Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema. 7. Any history of anaphylaxis in relation to vaccination. 8. Pregnancy, lactation or willingness/intention to become pregnant during the study. 9. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ). 10. History of serious psychiatric condition likely to affect participation in the study. 11. Bleeding disorder (eg. Factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture. 13\. Individuals who have previously experienced episodes of capillary leak syndrome. 14\. History of confirmed major thrombotic event (including cerebral venous sinus thrombosis, deep vein thrombosis, pulmonary embolism). 15\. History of antiphospholipid syndrome. 16. History of prior receipt of unfractionated heparin. 17. History of heparin induced thrombocytopenia. 18. Any other serious chronic illness requiring hospital specialist supervision. 19\. Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week. 20. Suspected or known injecting drug abuse in the 5 years preceding enrolment. 21. Detectable circulating hepatitis B surface antigen (HBsAg). 22. Seropositive for hepatitis C virus (antibodies to HCV). 23. Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis. 24. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data. 25\. Inability of the study team to contact the volunteer's GP to confirm medical history and safety to participate. 26. Receipt of any prior rabies vaccine, including an incomplete course. 27. Require or will require rabies vaccination during the first 8 weeks of the study period (e.g. through planned travel to high risk enzootic areas of through work which may lead to exposure and for which rabies vaccination is usually required/recommended).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and tolerability of ChAdOx2 RabG in healthy volunteers given as a standalone vaccine at different doses assessed by the occurrence of solicited adverse events. | Assessment of solicited AEs in the first 7 days post vaccination | Occurrence of solicited local and systemic adverse events (i.e: pain, redness, swelling and pruritus at injection site and temperature, feverishness, myalgia, arthralgia, malaise, headache, fatigue and nausea). |
| Safety and tolerability of ChAdOx2 RabG in healthy volunteers given as a standalone vaccine at different doses assessed by the occurrence of serious adverse events. | SAEs will be collected from enrolment until the end of the follow-up period.(8 weeks) | Occurrence of serious adverse events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immunogenicity of the ChAdOx2 RabG vaccine | Day 365 | Rapid fluorescent focus inhibition test (RFFIT) of virus neutralising antibody |
Other
| Measure | Time frame | Description |
|---|---|---|
| Immunological memory induced by ChAdOx2 RabG | Between days 365 and 386 | Virus neutralizing antibody will be measured before and in the course of immunisation with IRVs during an optional extended follow-up. |
| Timecourse of EBV and CMV shedding | Study Duration (386 days) | Measured by quantitative PCR. |
| Level of EBV and CMV shedding | Study Duration (386 days) | Measured by quantitative PCR. |
Countries
United Kingdom
Outcome results
None listed